



## **Promotions and evolutions within the AdBio Partners' management team**

**Paris, France, 13 January 2025** - AdBio Partners, Europe's leading life sciences seed fund, today announced a number of changes to its management team. These changes are an important step in the strategic and operational development of the management company.

### **Clément Bertholet promoted to Managing Partner**

Clément Bertholet, appointed Partner in 2023, has been promoted to Managing Partner. In addition to making new investments and representing AdBio Partners on the boards of several portfolio companies, Clément is already heavily involved in the life, management and strategic development of the management company. He joined the AdBio Partners ecosystem in an operational role, playing a key role in the initial development of Tabor Therapeutics, and subsequently co-founded and managed Calida Therapeutics, a company specialized in thrombo-inflammation.

Clément holds a degree in Biology from the Ecole Normale Supérieure (ENS Paris-Saclay), an MSc in Molecular Biology and Health and is a French State senior officer (Corps des Mines engineer in chief).

After gaining experience in research at the Institut Curie (Paris) and Cancer Research UK (London), he began his career at BNP Paribas CIB (New York) and the Ministry of the Economy and Finance, where he held positions of great responsibility and technical legal and financial expertise, including a tenure as Deputy Interministerial Delegate for Business Restructuring. In this capacity, he helped saving more than 20,000 jobs and strategic industrial assets for France, and created and then managed a €500m credit line. He has also represented the Treasury on the boards of public institutions.

His dual expertise in science and in social and financial negotiations, as well as his very good knowledge of public institutions, enable him to bring a unique approach to AdBio Partners' investments. In his new role, he will continue to work alongside Alain Huriez and Emma Gasol to pursue the vision and strategic development of the management company.

### **Geoffroy de Ribains takes on new responsibilities as Venture Partner**

Geoffroy de Ribains is taking on the role of Venture Partner to focus on entrepreneurial and operational projects in the AdBio Partners ecosystem, while continuing to provide his expertise in the evaluation of certain projects.

With over 20 years' experience in the biotech sector as an investor and entrepreneur, Geoffroy previously worked at Atlas Venture and Andera Partners, before co-founding and managing Step Pharma. More recently, as part of his operational role at AdBio Partners, he founded Gamut Therapeutics (acquired by SparingVision in 2021).



His rare skills in the creation and development of start-ups emerging from academic research and as an experienced investor will be key to the success of the entrepreneurial projects he supports.

### **Adrien Clavairoly promoted to Principal**

Adrien Clavairoly, who joined AdBio Partners at its creation in 2016, has been promoted to Principal. Adrien brings strong scientific expertise and plays a key role in identifying and evaluating projects. Adrien contributes to the development of several companies in the AdBio Partners portfolio as a member of the board of directors or as an observer.

A scientist by training, Adrien's academic career included a Master's degree in Cellular and Molecular Biology and a Master's degree in Integrative Biology and Physiology at the Université Pierre et Marie Curie. He trained in electrophysiology at Oxford University and the Institut Pasteur, and completed his doctorate at the Institut du Cerveau et de la Moelle épinière (ICM, Paris), conducting research into the genetics of neural stem cells in demyelinating diseases.

His in-depth scientific expertise, as well as his passion and curiosity on a daily basis, are invaluable assets for AdBio Partners and the companies we support.

### **About AdBio partners**

AdBio partners is an AMF-regulated management company that invests in seed capital in the life sciences, with a particular focus on therapeutic projects.

AdBio partners' unique strategy combines seed investment in promising projects with strong entrepreneurial support from the team to help the company grow.

Founded in 2016, AdBio partners has made 26 investments in France, Belgium, Spain with two seed funds.

The company has developed strong relationships with ecosystem players in Europe and has also attracted international venture capital syndicates to its portfolio companies. The team is made up of experienced entrepreneur-investors with extensive scientific, medical and operational knowledge.

[www.adbio.partners](http://www.adbio.partners)

---

Contact medias

**AdBio Partners**

[contact@adbio.partners](mailto:contact@adbio.partners)

---